Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPICE Trial: Cryoablation + Lucan-Sartuzumab + Immunotherapy in Advanced Cholangiocarcinoma
ChiCTR2600119932Phase 2Not yet recruiting
- Sponsor
- Lishui City Central Hospital
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lucansartuzumab in cholangiocarcinoma (CCA), sponsored by Lishui City Central Hospital. Primary endpoint: Objective Response Rate (ORR). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
lucansartuzumab
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR2600119932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119932.